Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app
Work Background
Axcynsis TherapeuticsChief Business Officer
Dec. 2024 - Feb. 2025New York City Metropolitan AreaLeading Axcynsis' $40M series A fundraising and supporting partnering of its proprietary, first-in-class AxcynDOT payload and IND-stage ADC therapeutics
PILA PHARMADirector Board of Directors
May. 2023 - Apr. 2024Malmö, Skåne County, SwedenDirector on the board with special insights into orphan drug development and US opportunities
DeckTherapeutics, Inc.Chief Executive Officer
Dec. 2020 - Apr. 2024New York City Metropolitan AreaLed Columbia University spinout DeckTherapeutics on its mission to pioneer neuroprotection using intravenous omega-3 diglyceride therapeutics. Secured funding from two institutional investors and a non-dilutive grant from the Bill & Melinda Gates Foundation. Oversaw the progression of the lead asset to late preclinical stage.
Gambit Bio LLCChief Executive Officer
Oct. 2019New York City Metropolitan AreaConsultancy providing strategy and business development and investment advisory services to life science investors and companies. Search and evaluation of late preclinical and early clinical opportunities.
Prophylix Pharma Holding ASDirector Board of Directors
Sep. 2019Tromso Area, Norway
Prophylix ASChief Executive Officer
Apr. 2015 - Sep. 2019Tromso Area, NorwayLed strategy, and business and organizational development to drive evolution to clinical-stage, orphan drug company and investor exit in transaction with US orphan drug specialist Rallybio (www.rallybio.com). Established and managed vital relationships with CMC, development, and commercial partners. Drove strategy to obtain dual FDA/EMA compliant product and secure feasible path to US and European markets.
Prophylix Pharma IncPresident
Oct. 2013 - Sep. 2019New York, NYEstablished and led US drug and business development activities. Built and managed key alliances, including with medical advisors, plasma suppliers, drug manufacturer, consultants, investors, regulators and other stakeholders based in North America.
Prophylix ASChief Business Officer
Aug. 2013 - Mar. 2015Greater New York City AreaDrove regulatory and partnering strategy development and implementation across North America and Europe. Steered subcontracting of drug manufacturing. Developed organization to a near-clinical stage company. Led investor presentations and interactions.
Prophylix Pharma ASEU Project Coordinator
Jun. 2012 - Jul. 2013Copenhagen Area, DenmarkCoordinator of the EU FP-7 project PROFNAIT (www.profnait.eu). The 11 organizations in the Northern European consortium seek to develop a new prophylactic treatment of the rare disease fetal/neonatal alloimmune thrombocytopenia (FNAIT).
Wiborg ApsSenior Consultant
Aug. 2009 - Jul. 2013HørsholmConsulted to diverse companies on biotech strategy and business development, scientific and commercial assessments/due diligence, valuations and deal structuring. Contributed directly to business transformation and investment decisions. Authored successful orphan drug applications to EMA and FDA.
DakoSenior Project Manager, Corporate Project Management Office
May. 2007 - Jul. 2008Glostrup, DenmarkManaged a large, international reagents development and pre-marketing project. Aligned development processes and quality standards across two countries, and achieved full integration on automated platform. Delivered product line launch on time and on budget. Dako is now Agilent Technologies.
LEO PharmaProcess Specialist, Regulatory Affairs
Dec. 2006 - Apr. 2007Ballerup, DenmarkDrove balanced scorecard and user requirement specifications for PV database.
Leo PharmaSenior Project Manager
Apr. 2005 - Nov. 2006Ballerup, DenmarkLed implementation of formal project management in Discovery organization, steering committee facilitation, and optimization of process for scientific assessment of in-licensing opportunities.
BioImageProject Manager
Nov. 2000 - Mar. 2005Gladsaxe, DenmarkFull-time project management and commercialization of drug discovery projects. Represented company in commercial discussions with AstraZeneca, Becton Dickinson, Schering, and more.
UNIZYME Laboratories A/SResearch Scientist
Aug. 1996 - Oct. 2000Hørsholm, DenmarkPerformed gene cloning and engineering and protein expression, purification, and characterization. Drove external collaborations with academic groups that led the first X-ray structures of a 160,000 kDa dipeptidyl peptidase.
Intch is a Professional Networking App for the Future of WorkSee more people like Soren on Intch
300k+ people
130+ countries
AI matching
Get Intch if you'd like to
538069 people
21
Education Consultant
15
Human Resources @ UB Greensfelder
15
Principal Consultant @ Marketing Endeavors Strategic Consulting
30233 people
15
Marketing Executive @ LivesMarket
22
Military @ Us Army
18
Sales Executive @ CNPC